Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?

BACKGROUND: The survival rates in population-based series of glioblastoma (GBM) differ substantially from those reported in clinical trials. This discrepancy may be attributed to that patients recruited to trials tend to be younger with better performance status. However, the proportion and characte...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neurooncol Adv
Egile Nagusiak: Skaga, Erlend, Skretteberg, Marthe Andrea, Johannesen, Tom Børge, Brandal, Petter, Vik-Mo, Einar O, Helseth, Eirik, Langmoen, Iver A
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2021
Gaiak:
Clinical Investigations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7914075/
https://ncbi.nlm.nih.gov/pubmed/33665615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdab008
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak